GH Company Profile and Key Details

Q: Who are the executives of GH?

Ms. Ines Dahne-SteuberChief Operating OfficerMr. Andy AmentSenior Vice President of OperationsDr. Craig Eagle M.D.Chief Medical OfficerDr. AmirAli Talasaz Ph.D.Co-Chief Executive Officer & DirectorMs. Jennifer HigginsVice President of Public AffairsMr. Kumud KaliaChief Information Officer & Chief Operating Officer of OncologyMr. Christopher FreemanChief Commercial OfficerDr. Helmy Eltoukhy Ph.D.Co-Founder, Co-Chief Executive Officer & ChairmanDarya ChudovaSenior Vice President of TechnologyMr. John G. SaiaChief Legal Officer & Corporation Sec.Ms. Darya ChudovaChief Technology Officer

NASDAQ : GH

Guardant Health

$105.34

3.49+3.43%

At Close 4:00 PM

65.78

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Guardant Health, Inc. (GH) stock surged +3.43%, trading at $105.34 on NASDAQ, up from the previous close of $101.85. The stock opened at $101.43, fluctuating between $99.50 and $106.73 in the recent session.

Stock Snapshot

101.85

Prev. Close

13.63B

Market Cap

99.5

Day Low

-32.71

P/E Ratio

-3.22

EPS (TTM)

-2.92

Cash Flow per Share

101.43

Open

129.37M

Number of Shares

106.73

Day High

95.22%

Free Float in %

1.34

Book Value

1.45M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 09, 2026	101.08	106.73	99.50	105.34	1.56M
Feb 06, 2026	100.77	102.70	97.52	101.85	1.83M
Feb 05, 2026	105.27	107.76	97.88	98.36	5.32M
Feb 04, 2026	113.05	113.99	102.21	106.15	3.83M
Feb 03, 2026	115.95	118.00	111.33	113.05	1.64M
Feb 02, 2026	113.68	116.27	112.41	114.90	1.69M
Jan 30, 2026	111.59	114.97	108.74	114.04	1.98M
Jan 29, 2026	107.68	110.48	105.78	110.48	1.17M
Jan 28, 2026	114.86	115.25	109.25	109.73	1.6M
Jan 27, 2026	114.00	117.00	113.53	114.59	1.28M
Jan 26, 2026	114.15	117.74	113.02	114.74	1.11M
Jan 23, 2026	116.50	118.29	113.67	114.75	1.47M
Jan 22, 2026	116.41	120.74	115.95	117.28	2.83M
Jan 21, 2026	115.10	116.41	110.31	115.75	2.21M
Jan 20, 2026	110.50	114.97	109.11	114.87	1.92M
Jan 16, 2026	111.98	115.54	110.09	112.14	2.06M
Jan 15, 2026	108.93	112.53	108.39	111.98	1.45M
Jan 14, 2026	106.87	109.08	104.66	108.60	1.39M
Jan 13, 2026	107.99	108.38	103.81	106.89	1.48M
Jan 12, 2026	113.00	113.91	103.80	107.57	2.36M

Contact Details

Palo Alto, CA 94063

United States

https://guardanthealth.com 855 698 8887

About Company

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Stock Peers

IDXX

-4.82-0.75%

IDEXX Laboratories, Inc.$639.79 MEDP

-11.69-2.16%

Medpace Holdings, Inc.$530.35 NTRA

7.54+3.71%

Natera, Inc.$210.58 ICLR

3.98+2.64%

ICON Public Limited Company$154.57 ILMN

-2.47-2.06%

Illumina, Inc.$117.25 EXAS

0.14+0.14%

Exact Sciences Corporation$103.32 GRAL

0.33+0.33%

GRAIL, Inc.$100.40 BLLN

1.8+1.99%

BillionToOne, Inc.$92.41 RDNT

-0.09-0.13%

RadNet, Inc.$69.15 TWST

-1.77-3.59%

Twist Bioscience Corporation$47.47

Company Overview

Guardant Health, Inc. (NASDAQ:GH) closed at $105.34 USD, gaining $3.49 (3.43%) from the previous close of $101.85. The stock is currently mid-range between its 52-week high and low $34.88 and $120.74. With a market capitalization of about $13.63 billion, Guardant Health, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.65). Key stats such as the average daily volume over the past year has been around 2.12 million shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Guardant Health, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Helmy Eltoukhy, the company employs approximately 1,999 people and listed since October 04, 2018. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.

Technical Performance

GH has shown sold momentum, gaining 6.79% over the past week and 75.48% over the past quarter, though year-to-date performance is up 12.46%. Short-term trend indicators are bearishly aligned (SMA20 -4.8%, SMA50 -1.06%, SMA200 48.97%). The stock’s 14-day RSI is 46.09 (neutral), while the ATR of 5.89 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.75% below its high and over 202.01% above its low. Average 10-day trading volume of 2.55 million shares is slightly above the 3-month average of 2.07 million, indicating heightened recent market interest.

Valuation Metrics

Guardant Health, Inc. trades at a P/E ratio of -33.07, slightly below the S&P 500 average, with a price-to-sales ratio of 15.15 and a price-to-book ratio of -37.21 indicating negative book value, which may reflect financial stress. The P/FCF stands at -52.13, also below market averages.

Dividend & Fair Value

Guardant Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $53.03. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Guardant Health, Inc. generated EPS of -$3.21 over the past year. Five-year average earnings growth is -33.61%. Wall Street analysts project EPS growth of 23.81% annually over the next five years. The latest quarter delivered EPS of -$0.74. The next quarter is forecast at -$0.76. Next year's EPS is expected at $4.46. Analyst sentiment is bullish. Analyst rating data shows there are 27 Strong Buy ratings, 23 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $155.00 to $50.00. The high target offers 47.14% upside. The low target suggests -52.53% downside. The mean target is $84.47. This offers -19.81% upside. Guardant Health, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended October 29, 2025, missed forecasts by 54.17%. The prior quarter beat by -15.38%. Over the last six quarters, Apple has recorded several small beats. These include -15.79% in August 07, 2024.

Shareholding & Insider Activity

Guardant Health, Inc. has 124.71 million shares outstanding. The public float is 119.56 million shares, elevated short interest at 7.91% of float. This equals 9.40 million shares. The short ratio is 4.22 days. Institutional investors hold 103.78% of the float. Insiders own 4.5%. Eltoukhy Helmy holds 2.05 million shares, Talasaz AmirAli has 168.22 thousand shares and Saia John G. has 43.17 thousand shares. Over the past six months, insider transactions show net selling. They sold 59.22 thousand shares across 26 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Guardant Health generated $563.95M in revenue, or $5.04 per share. Gross margin was 59.74%, operating margin -99.75%, and net profit margin -85.02%. Returns are negative, with ROA at -26.84% and ROE at -302.14%.
On valuation metrics, Guardant Health trades at a P/E of -33.07, P/S of 15.15 and P/B of -37.21. The current ratio is 3.50 and quick ratio is 3.12. Operationally, the company’s inventory turnover is 3.61 and cash conversion cycle is 125.24 days. Debt-to-equity is -3.74, supported by a cash flow-to-debt ratio of -0.17.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Guardant Health posted revenue of $563.95M, down slightly from $449.54M in the prior quarter. Gross profit was $336.90M (margin 59.74%). Operating income was - $562.52M (margin -99.7%). Net income was- $479.45M (EPS - $4.28).
The company ended the quarter with $1.17B in cash and short-term investments, a total debt of $1.35B, and net debt of $220.23M. Total assets were $1.79B, with equity of $158.68M. Financials further reflected weakness, with operating cash flow of - $324.98M, free cash flow of - $345.46M, and capital expenditures of - $20.49M.

Price Forecast & Outlook

Our AI price prediction model suggests that Guardant Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.37%, with price expected at $98.63 by February 23, 2026, within a range of $94.73 to $102.80 3-Month Outlook: Projected fall of -38.94%, reaching $64.32 by May 07, 2026, with a range of $62.11 to $66.68. 1-Year Outlook: Projected gain of 16.44%, with price at $122.66 by February 09, 2027, within a range of $116.66 to $129.07.

Key Takeaways

Guardant Health, Inc. (NASDAQ:GH) shares are up 12.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Guardant Health, Inc. trading at a premium to the broader market with a P/E of -33.07. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $76.76, suggesting -27.13% downside. Our AI forecast model points to short-term weakness (-6.37% over two weeks), a medium-term fall (-38.94% over three months), and a longer-term gain (16.44% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Guardant Health, Inc. (GH) stock price?

Guardant Health, Inc. (NASDAQ: GH) stock price is $105.34 in the last trading session. During the trading session, GH stock reached the peak price of $106.73 while $99.50 was the lowest point it dropped to. The percentage change in GH stock occurred in the recent session was 3.43% while the dollar amount for the price change in GH stock was $3.49.

GH's industry and sector of operation?

The NASDAQ listed GH is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Guardant Health, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GH?

Ms. Ines Dahne-Steuber
Chief Operating Officer
Mr. Andy Ament
Senior Vice President of Operations
Dr. Craig Eagle M.D.
Chief Medical Officer
Dr. AmirAli Talasaz Ph.D.
Co-Chief Executive Officer & Director
Ms. Jennifer Higgins
Vice President of Public Affairs
Mr. Kumud Kalia
Chief Information Officer & Chief Operating Officer of Oncology
Mr. Christopher Freeman
Chief Commercial Officer
Dr. Helmy Eltoukhy Ph.D.
Co-Founder, Co-Chief Executive Officer & Chairman
Darya Chudova
Senior Vice President of Technology
Mr. John G. Saia
Chief Legal Officer & Corporation Sec.
Ms. Darya Chudova
Chief Technology Officer

How GH did perform over past 52-week?

GH's closing price is 202.01% higher than its 52-week low of $34.88 where as its distance from 52-week high of $120.74 is -12.76%.

How many employees does GH have?

Number of GH employees currently stands at 1,999.

Link for GH official website?

Official Website of GH is: https://guardanthealth.com

How do I contact GH?

GH could be contacted at phone 855 698 8887 and can also be accessed through its website. GH operates from 505 Penobscot Drive, Palo Alto, CA 94063, United States.

How many shares of GH are traded daily?

GH stock volume for the day was 1.45M shares. The average number of GH shares traded daily for last 3 months was 2.12M.

What is the market cap of GH currently?

The market value of GH currently stands at $13.63B with its latest stock price at $105.34 and 129.37M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1999
Beta	1.65
Sales or Revenue	$563.95M
5Y Sales Change%	0.689%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

GH Company Profile and Key Details

Guardant Health

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook